By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.

ERBB3 as a therapeutic target in glioblastoma: overexpression can make the difference

De Bacco F.;Boccaccio C.
2021

Abstract

By exploiting an integrated experimental platform based on patient-derived cancer stem cells, we identified a glioblastoma subset characterized by inheritable Erb-B2 Receptor Tyrosine Kinase 3 (ERBB3) overexpression, metabolic dependency on ERBB3 signaling, and liability to ERBB3 targeting. We provide insights on why some glioblastomas may rely on ERBB3 and how to recognize them.
MOLECULAR & CELLULAR ONCOLOGY
8
5
1990677
1990678
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632286/
cancer stem cell; ERBB3; glioblastoma; targeted therapies
De Bacco F.; Boccaccio C.
File in questo prodotto:
File Dimensione Formato  
De Bacco & Boccaccio_Mol Cell Oncol_2022_PubMedC.pdf

accesso aperto

Descrizione: Aticolo Principale
Tipo di file: PDF EDITORIALE
Dimensione 438.78 kB
Formato Adobe PDF
438.78 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1858353
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact